Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 6/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | CNR2 | P34972 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | BLM | P54132 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.45 |
| ▸ | SELP | P16109 | 1/20 | 0.45 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2124347 | 0.88 | CASP2 (0.44) | NAAACNR1ALDH1A1MEN1KMT2A | |
| SCHEMBL16560390 | 0.88 | EPHX2 (0.45) | NAAACNR1MEN1KMT2AFAAH | |
| SCHEMBL25516099 | 0.86 | CASP2 (0.42) | NAAACNR1MEN1KMT2AFAAH | |
| SCHEMBL5836462 | 0.86 | CNR1 (0.46) | NAAACNR1ALDH1A1CNR2MEN1 | |
| SCHEMBL25516101 | 0.86 | CASP2 (0.42) | NAAACNR1MEN1KMT2AFAAH | |
| SCHEMBL24982767 | 0.86 | MEN1 (0.46) | NAAACNR1MEN1KMT2AFAAH | |
| SCHEMBL19544544 | 0.86 | MEN1 (0.46) | NAAACNR1MEN1KMT2AFAAH | |
| SCHEMBL25415126 | 0.86 | NAAA (0.59) | NAAACNR1ALDH1A1CNR2MEN1 | |
| SCHEMBL5165598 | 0.86 | NAAA (0.59) | NAAACNR1ALDH1A1CNR2MEN1 | |
| SCHEMBL17874807 | 0.85 | NAAA (0.56) | NAAACNR1ALDH1A1CNR2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321048-A1 | ANTIBODY DRUG CONJUGATES COMPRISING STING AGONISTS | MERSANA THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230172910-A1 | ANTIBODY DRUG CONJUGATES COMPRISING STING AGONISTS | MERSANA THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20110172390-A1 | Protein-Proteophore Complexes | ASCENDIS PHARMA A/S (DK) | 2011-07-14 | — | — | US | disclosed |
| US-20070020224-A1 | Protein-proteophore complexes | ASCENDIS PHARMA GMBH (DE) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172390-A1 | Protein-Proteophore Complexes | PSMG3, PSME1, PSMD11 | NAAA 1854/4885CNR1 4663/4885ALDH1A1 4508/4885 |
| US-20070020224-A1 | Protein-proteophore complexes | PSMG3, PSME1, PSMD11 | NAAA 1854/4885CNR1 4663/4885ALDH1A1 4508/4885 |
| US-20230321048-A1 | ANTIBODY DRUG CONJUGATES COMPRISING STING AGONISTS | STING1, CGAS, IFNAR1 | NAAA 1904/4885CNR1 2247/4885ALDH1A1 2462/4885 |
| US-20230172910-A1 | ANTIBODY DRUG CONJUGATES COMPRISING STING AGONISTS | STING1, CGAS, IFNAR1 | NAAA 1904/4885CNR1 2247/4885ALDH1A1 2462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.